Nuclease activity and ultrastructural effects of new sulfonamides with anti-leishmanial and trypanocidal activities

Parasitology International

Volumn 61, Issue 4, 2012, Pages 604-613

  Bilbao Ramos, Pablo ^a   Galiana Roselló, Cristina ^b   Dea Ayuela, M Auxiliadora ^a,b   González Alvarez, Marta ^c   Vega, Celeste ^d   Rolón, Miriam ^d   Pérez Serrano, Jorge ^e   Bolás Fernández, Francisco ^a   González Rosende, M Eugenia ^b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSIDAD CEU CARDENAL HERRERA   (Spain)

^c MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^d CENTRO PARA EL DESARROLLO DE LA INVESTIGACIÓN CIENTÍFICA   (Paraguay)

^e UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Electron microscopy; Leishmania spp.; Nuclease activity; Sulfonamides; Trypanosoma cruzi

Indexed keywords

4 CHLORO N 5 METHYL THIAZOL 2 YL BENZENESULFONAMIDE; 4 NITRO N PYRIMIDIN 2 YLBENZENESULFONAMIDE; ANTILEISHMANIAL AGENT; ANTITRYPANOSOMAL AGENT; BENZNIDAZOLE; MILTEFOSINE; NUCLEASE; PLASMID DNA; REACTIVE OXYGEN METABOLITE; SULFONAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CELL MEMBRANE; CELL NUCLEUS; CONTROLLED STUDY; DNA STRAND; DRUG MECHANISM; IN VITRO STUDY; KINETOPLAST; LEISHMANIA; LEISHMANIA BRAZILIENSIS; LEISHMANIA INFANTUM; MACROPHAGE; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY; TRYPANOSOMA CRUZI; ULTRASTRUCTURE;

ANIMALS; ANTIPROTOZOAL AGENTS; CELL LINE; CELL SURVIVAL; DEOXYRIBONUCLEASES; LEISHMANIA INFANTUM; MACROPHAGES; MICE; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, ELECTRON, TRANSMISSION; MOLECULAR STRUCTURE; NITROIMIDAZOLES; PHOSPHORYLCHOLINE; SULFONAMIDES;

LEISHMANIA INFANTUM; TRYPANOSOMA CRUZI;

EID: 84866001561     PISSN: 13835769     EISSN: 18730329     Source Type: Journal    
DOI: 10.1016/j.parint.2012.05.015     Document Type: Article

References (55)

1. Nussbaum K., Honek J., Cadmus C.M., Efferth T. Trypanosomatid parasites causing neglected diseases. Current Medicinal Chemistry 2010, 17:1594-1617.
2. 30 Dec 2011, date last accessed. http://www.who.int/topics/en.
3. 30 Dec 2011, date last accessed. http://www.dndi.org.
4. Graebin C.S., Uchoa F.D., Bernardes L.S.C., Campo V.L., Carvalho I., Eifler-Lima V.L. Antiprotozoal agents: an overview. Anti-infective Agents in Medicinal Chemistry 2009, 8:345-366.
5. Croft S.L. Kinetoplastida new therapeutic strategies. Parasite 2008, 15:522-527.
6. Kedzierski L., Sakthianandeswaren A., Curtis J.M., Andrews P.C., Junk P.C., Kedzierska K. Leishmaniasis: current treatment and prospects for new drugs and vaccines. Current Medicinal Chemistry 2009, 16:599-614.
7. Croft S.L., Sundar S., Fairlamb A.H. Drug resistance in Leishmaniasis. Clinical Microbiology Reviews 2006, 19:111-126.
8. Filardi L.S., Brener Z. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Transactions of the Royal Society of Tropical Medicine and Hygiene 1987, 81:755-759.
9. Richard J.V., Werbovetz K.A. New antileishmanial candidates and lead compounds. Current Opinion in Chemical Biology 2010, 14:447-455.
10. Cerecetto H., González M. Synthetic medicinal chemistry in Chagas' disease: compounds at the final stage of "hit-to-lead" phase. Pharmaceuticals 2010, 3:810-838.
11. Argyropoulou I., Geronikaki A., Vicini P., Zani F. Synthesis and biological evaluation of sulfonamide thiazole and benzothiazole derivatives as antimicrobial agents. Arkivoc 2009, 6:89-102.
12. Mitscher L.A., Lemke T.L., Gentry E.J. Antibiotics and antimicrobial agents. Foye's principles of medicinal chemistry 2008, 1028-1083. Lippincott Williams and Wilkins, Philadelphia. 6th ed. T.L. Lemke, D.A. Williams (Eds.).
13. Vullo D., Innocenti A., Supuran C.T. Diuretics with carbonic anhydrase inhibitory activity: toward novel applications for sulfonamide drugs. Drug design of zinc-enzyme inhibitors 2009, 155-170. John Wiley and Sons, New Yersey. C.T. Supuran, J.-Y. Winum (Eds.).
14. Supuran C.T., Scozzafava A. Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opinion on Therapeutic Patents 2000, 10:575-600.
15. Navarrete-Vazquez G., Paoli P., León-Rivera I., Villalobos-Molina R., Medina-Franco J.L., Ortiz-Andrade R., Estrada-Soto S., Camini G., Diaz-Coutiño D., Gallardo-Ortiz I., Martínez-Mayorga K., Moreno-Díaz H. Synthesis, in vitro and computational studies of protein tyrosine phosphatase 1B inhibition of a small library of 2-arylsulfonylaminobenzothiazoles with antihyperglycemic activity. Bioorganic & Medicinal Chemistry 2009, 17:3332-3341.
16. Selam J.L. Pharmacokinetics of hypoglycemic sulfonamides: Ozidia, a new concept. Diabetes & Metabolism 1997, 23:39-43.
17. Thornber C.W. Isosterism and molecular modification in drug design. Chemical Society Reviews 1979, 8:563-580.
18. Ghorab M., Ragab A., Hamed M.M. Design, synthesis and anticancer evaluation of novel tetrahydroquinoline derivatives containing sulfonamide moiety. European Journal of Medicinal Chemistry 2009, 44:4211-4217.
19. Hu L., Li Z., Jiang J.D., Boykin D.W. Novel diaryl or heterocyclic sulfonamides as antimitotic agents. Anti-Cancer Agents in Medicinal Chemistry 2008, 8:739-745.
20. Rostom S.A.F. Synthesis and in vitro antitumor evaluation of some indeno [1,2-c]pyrazol(in)es substituted with sulfonamide, sulfonylurea(-thiourea) pharmacophores, and some derived thiazole ring systems. Bioorganic & Medicinal Chemistry 2006, 14:6475-6485.
21. Supuran C.T., Casini A., Mastrolorenzo A., Scozzafava A. COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents. Mini Reviews in Medicinal Chemistry 2004, 4:625-632.
22. Wolfe C., Hicks C. Profile of darunavir in the management of treatment-experienced HIV patient. HIV/AIDS: Research and Palliative Care 2009, 1:13-21.
23. Stranix B.R., Lavallée J.F., Sevigny G., Yelle J., Perron V., LeBerre N., Herbart D., Wu J.J. Lysine sulfonamides as novel HIV-protease inhibitors: Nε-acyl aromatic α-amino acids. Bioorganic & Medicinal Chemistry Letters 2006, 16:3459-3462.
24. Supuran C.T., Innocenti A., Mastrolorenzo A., Scozzafava A. Antiviral sulfonamide derivatives. Mini Reviews in Medicinal Chemistry 2004, 4:189-200.
25. Martyn D.C., Cortese J.F., Tyndall E., Dick J., Mazitschek R., Munoz B., Clardy J. Antiplasmodial activity of piperazine sulfonamides. Bioorganic & Medicinal Chemistry Letters 2010, 20:218-221.
26. Hernández-Núñez E., Tlahuext H., Moo-Puc R., Torres-Gómez H., Reyes-Martínez R., Cedillo-Rivera R., Nava-Zuazo C., Navarrete-Vazquez G. Synthesis and in vitro trichomonicidal, giardicidal and amebicidal activity of N-acetamide(sulfonamide)-2-methyl-4-nitro-1H-imidazoles. European Journal of Medicinal Chemistry 2009, 44:2975-2984.
27. Ekoue-Kovi K., Yearick K., Iwaniuk D.P., Natarajan J.K., Alumasa J., de Dios A.C., Roepe P.D., Wolf C. Synthesis and antimalarial activity of new 4-amino-7-chloroquinolyl amides, sulfonamides, ureas and thioureas. Bioorganic & Medicinal Chemistry 2009, 17:270-283.
28. Parai M.K., Panda G., Srivastava K., Puri S.K. Design, synthesis and antimalarial activity of benzene and isoquinoline sulfonamide derivatives. Bioorganic & Medicinal Chemistry Letters 2008, 18:776-778.
29. Krungkrai J., Krungkrai S.R., Supuran C.T. Malarial parasite carbonic anhydrase and its inhibitors. Current Topics in Medicinal Chemistry 2007, 7:909-917.
30. Domínguez J.N., León C., Rodrigues J., Gamboa de Domínguez N., Gut J., Ph Rosental Synthesis and antimalarial activity of sulfonamide chalcone derivatives. Il Fármaco 2005, 60:307-311.
31. Norose K., Aosai F., Mun H.S., Yano A. Effects of sulfamethoxazole on murine ocular toxoplasmosis in interferon-γ knockout mice. Investigative Ophthalmology & Visual Science 2006, 47:265-271.
32. Greif G., Harder A., Heberkorn A. Chemotherapeutic approaches to protozoa: Ciccidiae-current level of knowledge and outlook. Parasitology Research 2001, 87:973-975.
33. van der Ven A.J., de Ven EM Schoondermark-van, Camps W., Melchers W.J., Koopmans P.P., van der Meer J.W., Galama J.M. Anti-Toxoplasma effect of pyrimethamine, trimethoprim and sulfonamides alone and in combination: implications for therapy. The Journal of Antimicrobial Chemotherapy 1996, 38:75-80.
34. Pagliero R.J., Lusvarghi S., Pierini A.B., Brun R., Mazzieri M.R. Synthesis, stereoelectronic characterization and antiparasitic activity of new 1-benzenesulfonyl-2-methyl-1,2,3,4-tetrahydroquinolines. Bioorganic & Medicinal Chemistry 2010, 18:142-150.
35. Goodarzi M., da Cunha E.F., Freitas M.P., Ramalho T.C. QSAR and docking studies of novel antileishmanial diaryl sulfides and sulfonamides. European Journal of Medicinal Chemistry 2010, 45:4879-4889.
36. da Silva L.E., de Sousa P.T., Jr Maciel E.N., Korting-Nunes R., Eger I., Steindel M., Andrade-Rebelo R. In vitro antiprotozoal evaluation of zinc and copper complexes based on sulfonamides containing 8-aminoquinoline ligands. Letters in Drug Design & Discovery 2010, 7:679-685.
37. Souza A.M., Castro H.C., Brito M.A., Andrighetti-Fröner C.R., Magalhaes U., Oliveira K.N., Gaspar-Silva D., Pacheco L.K., Joussef A.C., Steindel M., Simoes C.M., Santos D.O., Alburquerque M.G., Rodrigues C.R., Nunes R.J. Leishmania amazonensis growth inhibitors: biological and theoretical features of sulfonamide 4-methoxychalcone derivatives. Current Microbiology 2009, 59:374-379.
38. Khan K.M., Khan M.Z., Taha M., Maharvi G.M., Saify Z.S., Parveen S., Choudhary M.I. Leishmanicidal potential of N-substituted morpholine derivatives: synthesis and structure-activity relationships. Natural Product Research 2009, 23:479-484.
39. Altenkämper M., Bechem B., Perruchon J., Heinrich S., Madel A., Ortmann R., Dahse H.M., Freunscht E., Wang Y., Rath J., Stich A., Hitzler M., Chiba P., Lanzer M., Schlitzer M. Antimalarial and antitrypanosomal activity of a series of amide and sulfonamide derivatives of a 2,5-diaminobenzophenone. Bioorganic & Medicinal Chemistry 2009, 17:7690-7697.
40. da Silva L.E., Joussef A.C., Pacheco L.K., da Silva D.G., Steindel M., Rebelo R.A., Schmidt B. Synthesis and in vitro evaluation of leishmanicidal and trypanocidal activities of N-quinolin-8-yl-arylsulfonamides. Bioorganic & Medicinal Chemistry 2007, 15:7553-7560.
41. Ajibade P.A., Kolawole G.A., Brien P.O. Metal complexes of 4-amino-N-(2-pyrimidinyl)benzene sulfonamide: synthesis, characterization and antiprotozoal studies. Synthesis and Reactivity in Inorganic, Metal-Organic, and Nano-Metal Chemistry 2007, 37:653-659.
42. George T.G., Endeshaw M.M., Morgan R.E., Mahasenan K.V., Delfín D.A., Mukherjee M.S., Yakovich A.J., Fotie J., Li C., Werbovetz K.A. Synthesis, biological evaluation, and molecular modeling of 3,5-substituted-N1-phenyl-N4, N4-di-n-butylsulfanilamides as antikinetoplastid antimicrotubule agents. Bioorganic & Medicinal Chemistry 2007, 15:6071-6079.
43. 4-substituted 3,5-dinitro sulfanilamides against African trypanosomes and Leishmania. Journal of Medicinal Chemistry 2004, 47:1823-1832.
44. Chibale K., Haupt H., Kendrick H., Yardley V., Saravanamuthu A., Fairlamb A.H., Croft S.L. Antiprotozoal and cytotoxicity evaluation of sulfonamide and urea analogues of quinacrine. Bioorganic & Medicinal Chemistry Letters 2001, 11:2655-2657.
45. 1-propylglycinamide. Bioorganic & Medicinal Chemistry 2009, 17:7449-7456.
46. Ameen M. Cutaneous and mucocutaneous leishmaniasis: emerging therapies and progress in disease management. Expert Opinion on Pharmacotherapy 2010, 11:557-569.
47. 30 Dec 2011, date last accessed. http://www.who.int/mediacentre/factsheets/fs340/en/index.html.
48. Méndez S., Nell M., Alunda J.M. Leishmania infantum: infection of macrophages in vitro with promastigotes. International Journal of Parasitology 1996, 26:619-622.
49. Vega C., Rolón M., Martínez-Fernández A.R., Escario J.A., Gómez-Barrio A. A new pharmacological screening assay with Trypanosoma cruzi epimastigotes expressing beta-galactosidase. Parasitology Research 2005, 95:296-298.
50. Pérez-Serrano J., Grosman C., Urrea-París M.A., Denegri G., Casado N., Rodríguez-Caabeiro F. Depolarization of the tegument precedes morphological alterations in Echinococcus granulosus protoscoleces incubated with ivermectin. Parasitology Research 2001, 87:804-807.
51. Muelas-Serrano S., Pérez-Serrano J., Gómez-Barrio A., Arán V.J., Rodríguez-Caabeiro F. Ultrastructural alterations induced by nifurtimox and another nitro derivative on epimastigotes of Trypanosoma cruzi. Parasitology Research 2002, 88:97-101.
52. Drevensek P., Zupancic T., Pihlar B., Jerala R., Kolitsch U., Plaper A., Turel I. Mixed-valence Cu(II)/Cu(I) complex of quinolone ciprofloxacin isolated by a hydrothermal reaction in the presence of l-histidine: comparison of biological activities of various copper-ciprofloxacin compounds. Journal of Inorganic Biochemistry 2005, 99:432-442.
53. González-Álvarez M., Alzuet G., Borrás J., Pitié M., Meunier B. DNA cleavage studies of mononuclear and dinuclear copper(II) complexes with benzothiazolesulfonamide ligands. Journal of Biological Inorganic Chemistry 2003, 8:644-652.
54. Kehrer J.P. The Haber-Weiss reaction and mechanisms of toxicity. Toxicology 2000, 149:43-50.
55. Sigman D.S. Nuclease activity of 1,10-phenanthroline-copper ion. Accounts of Chemical Research 1986, 19:180-186.